PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study

NCT04189029 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2024-03-28

No results posted yet for this study

Summary

This is a prospective multicenter study to decipher phenotypic variability within patients with heart failure and preserved left ventricular ejection fraction (HFpEF). From a registry of heart failure patients (2500 anticipated) hospitalized in the participating centers in the last 3 years, up to 300 participants (with a final ratio of 3 HFpEF patients, 2 patients with heart failure and reduced ejection fraction (HFrEF) and 1 matched subjects without heart failure will be enrolled for an extensive phenotyping with physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters. Cluster analysis with machine learning methods will be performed to define phenogroups unique to the HFpEF patient population.

Conditions

Interventions

OTHER

Extensive phenotyping

Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.

Sponsors & Collaborators

  • BPIfrance

    collaborator OTHER
  • Sanofi

    collaborator INDUSTRY
  • Institut de Recherches Internationales Servier

    collaborator OTHER
  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV
  • BioSerenity

    collaborator INDUSTRY
  • Casis

    collaborator UNKNOWN
  • Firalis SA

    collaborator INDUSTRY
  • Fealinx

    collaborator UNKNOWN
  • Centre National de la Recherche Scientifique, France

    collaborator OTHER
  • ESPCI Paris

    collaborator OTHER
  • University of Paris 5 - Rene Descartes

    collaborator OTHER
  • Sorbonne University

    collaborator OTHER
  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-Sébastien HULOT, MD PhD · AP - HP, Hôpital Européen Georges-Pompidou, Paris, France

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2023-12-09
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189029 on ClinicalTrials.gov